Nexgel (NXGLW) Cash from Financing Activities (2018 - 2025)
Nexgel's (NXGLW) quarterly Cash from Financing Activities came in at -$1.0 million in Q4 2025, down 162.34% YoY from $1.7 million in Q4 2024, and down 154.05% on a QoQ basis from $1.9 million in Q3 2025.
Nexgel (NXGLW) Cash from Financing Activities (2018 - 2025) Analysis & Trends
Nexgel (NXGLW) has 8 years of Cash from Financing Activities data on file, last reported at -$1.0 million in Q4 2025.
- Quarterly Cash from Financing Activities fell 162.34% year-over-year to -$1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $630000.0 (down 83.2% YoY) and the FY2025 annual result came in at $630000.0, down 83.2% from the prior year.
- Cash from Financing Activities fell to -$1.0 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $13.2 million in Q4 2021 to a low of -$2.0 million in Q1 2022.
- A 5-year average of $968666.7 and a median of $43500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 46550.0% in 2024, down 6300.0% in 2024.
- Tracing NXGLW's Cash from Financing Activities over 5 years: stood at $13.2 million in 2021, then tumbled by 101.14% to -$150000.0 in 2022, then jumped by 296.0% to $294000.0 in 2023, then soared by 468.03% to $1.7 million in 2024, then tumbled by 162.34% to -$1.0 million in 2025.
- The last three Cash from Financing Activities figures came in at -$1.0 million (Q4 2025), $1.9 million (Q3 2025), and -$40000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Nexgel | 194,000.44 | -994,999.56 | 1.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.04 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -64,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Sep 30, 2023 | 88,000.00 |